Search

Your search keyword '"Axcrona, Ulrika"' showing total 147 results
Start Over Author "Axcrona, Ulrika"
147 results on '"Axcrona, Ulrika"'

8. 'High proliferative cribriform prostate cancer' defines a patient subgroup with an inferior prognosis.

Author

Bogaard, Mari, Skotheim, Rolf I, Maltau, Aase V, Kidd, Susanne G, Lothe, Ragnhild A, Axcrona, Karol, and Axcrona, Ulrika

Subjects
PROSTATE cancer, RADICAL prostatectomy, PROGNOSIS, DISEASE risk factors, PROGRESSION-free survival
Abstract

Aims: A cribriform pattern, reactive stroma (RS), PTEN, Ki67 and ERG are promising prognostic biomarkers in primary prostate cancer (PCa). We aim to determine the relative contribution of these factors and the Cancer of the Prostate Risk Assessment Postsurgical (CAPRA‐S) score in predicting PCa prognosis. Methods and results: We included 475 patients who underwent radical prostatectomy (2010–12, median follow‐up = 8.7 years). Cribriform pattern was identified in 57% of patients, PTEN loss in 55%, ERG expression in 51%, RS in 39% and high Ki67 in 9%. In patients with multiple samples from the same malignant focus and either PTEN loss or high Ki67, intrafocal heterogeneity for PTEN and Ki67 expression was detected in 55% and 89%, respectively. In patients with samples from two or more foci, interfocal heterogeneity was detected in 46% for PTEN and 6% for Ki67. A cribriform pattern and Ki67 were independent predictors of biochemical recurrence (BCR) and clinical recurrence (CR), whereas ERG expression was an independent predictor of CR. Besides CAPRA‐S, a cribriform pattern provided the highest relative proportion of explained variation for predicting BCR (11%), and Ki67 provided the highest relative proportion of explained variation for CR (21%). In patients with a cribriform pattern, high Ki67 was associated with a higher risk of BCR [hazard ratio (HR) = 2.83, P < 0.001] and CR (HR = 4.35, P < 0.001). Conclusions: High Ki67 in patients with a cribriform pattern identifies a patient subgroup with particularly poor prognosis, which we termed 'high proliferative cribriform prostate cancer'. These results support reporting a cribriform pattern in pathology reports, and advocate implementing Ki67. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only

Author

Hugosson, Jonas, primary, Månsson, Marianne, additional, Wallström, Jonas, additional, Axcrona, Ulrika, additional, Carlsson, Sigrid V., additional, Egevad, Lars, additional, Geterud, Kjell, additional, Khatami, Ali, additional, Kohestani, Kimia, additional, Pihl, Carl-Gustaf, additional, Socratous, Andreas, additional, Stranne, Johan, additional, Godtman, Rebecka Arnsrud, additional, and Hellström, Mikael, additional

Published
2022
Full Text
View/download PDF

14. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study

Author

Bancroft, Elizabeth K., Page, Elizabeth C., Castro, Elena, Lilja, Hans, Vickers, Andrew, Sjoberg, Daniel, Assel, Melissa, Foster, Christopher S., Mitchell, Gillian, Drew, Kate, Mæhle, Lovise, Axcrona, Karol, Evans, D. Gareth, Bulman, Barbara, Eccles, Diana, McBride, Donna, van Asperen, Christi, Vasen, Hans, Kiemeney, Lambertus A., Ringelberg, Janneke, Cybulski, Cezary, Wokolorczyk, Dominika, Selkirk, Christina, Hulick, Peter J., Bojesen, Anders, Skytte, Anne-Bine, Lam, Jimmy, Taylor, Louise, Oldenburg, Rogier, Cremers, Ruben, Verhaegh, Gerald, van Zelst-Stams, Wendy A., Oosterwijk, Jan C., Blanco, Ignacio, Salinas, Monica, Cook, Jackie, Rosario, Derek J., Buys, Saundra, Conner, Tom, Ausems, Margreet G., Ong, Kai-ren, Hoffman, Jonathan, Domchek, Susan, Powers, Jacquelyn, Teixeira, Manuel R., Maia, Sofia, Foulkes, William D., Taherian, Nassim, Ruijs, Marielle, den Enden, Apollonia T. Helderman-van, Izatt, Louise, Davidson, Rosemarie, Adank, Muriel A., Walker, Lisa, Schmutzler, Rita, Tucker, Kathy, Kirk, Judy, Hodgson, Shirley, Harris, Marion, Douglas, Fiona, Lindeman, Geoffrey J., Zgajnar, Janez, Tischkowitz, Marc, Clowes, Virginia E., Susman, Rachel, Ramón y Cajal, Teresa, Patcher, Nicholas, Gadea, Neus, Spigelman, Allan, van Os, Theo, Liljegren, Annelie, Side, Lucy, Brewer, Carole, Brady, Angela F., Donaldson, Alan, Stefansdottir, Vigdis, Friedman, Eitan, Chen-Shtoyerman, Rakefet, Amor, David J., Copakova, Lucia, Barwell, Julian, Giri, Veda N., Murthy, Vedang, Nicolai, Nicola, Teo, Soo-Hwang, Greenhalgh, Lynn, Strom, Sara, Henderson, Alex, McGrath, John, Gallagher, David, Aaronson, Neil, Ardern-Jones, Audrey, Bangma, Chris, Dearnaley, David, Costello, Philandra, Eyfjord, Jorunn, Rothwell, Jeanette, Falconer, Alison, Gronberg, Henrik, Hamdy, Freddie C., Johannsson, Oskar, Khoo, Vincent, Kote-Jarai, Zsofia, Lubinski, Jan, Axcrona, Ulrika, Melia, Jane, McKinley, Joanne, Mitra, Anita V., Moynihan, Clare, Rennert, Gad, Suri, Mohnish, Wilson, Penny, Killick, Emma, Moss, Sue, and Eeles, Rosalind A.

Published
2014
Full Text
View/download PDF

15. White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk

Author

Lønning, Per E., Berge, Elisabet O., Bjørnslett, Merete, Minsaas, Laura, Chrisanthar, Ranjan, Høberg-Vetti, Hildegunn, Dulary, Cécile, Busato, Florence, Bjørneklett, Silje, Eriksen, Christine, Kopperud, Reidun, Axcrona, Ulrika, Davidson, Ben, Bjørge, Line, Evans, D. Gareth, Howell, Anthony, Salvesen, Helga B., Janszky, Imre, Hveem, Kristian, Romundstad, Pål R., Vatten, Lars J., Tost, Jörg, Dørum, Anne, and Knappskog, Stian

Published
2018
Full Text
View/download PDF

19. Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer.

Author

Carm, Kristina T., Johannessen, Bjarne, Bogaard, Mari, Bakken, Anne Cathrine, Maltau, Aase V., Hoff, Andreas M., Axcrona, Ulrika, Axcrona, Karol, Lothe, Ragnhild A., and Skotheim, Rolf I.

Subjects
SOMATIC mutation, PROSTATE cancer, CIRCULATING tumor DNA, PROSTATE cancer patients, SOWING, METASTASIS
Abstract

Primary prostate cancer shows a striking intraorgan molecular heterogeneity, with multiple spatially separated malignant foci in the majority of patients. Metastatic prostate cancer, however, typically reveals more homogenous molecular profiles, suggesting a monoclonal origin of the metastatic lesions. Longitudinal mutational spectra, comparing multiple primary lesions with metastases from the same patients remain poorly defined. We have here analyzed somatic mutations in multisampled, spatio‐temporal biobanked lesions (38 samples from primary foci and 1 sample from each of 8 metastases from seven prostate cancer patients) applying a custom‐designed panel targeting 68 prostate cancer relevant genes. The metastatic samples were taken at time of primary surgery and up to 7 years later, and sampling included circulating tumor DNA in plasma or solid metastatic tissue samples. A total of 282 somatic mutations were detected, with a range of 0 to 25 mutations per sample. Although seven samples had solely private mutations, the remaining 39 samples had both private and shared mutations. Seventy‐four percent of mutations in metastases were not found in any primary samples, and vice versa, 96% of mutations in primary cancers were not found in any metastatic samples. However, for three patients, shared mutations were found suggesting the focus of origin, including mutations in AKT1, FOXA1, HOXB13, RB1 and TP53. In conclusion, the spatio‐temporal heterogeneous nature of multifocal disease is emphasized in our study, and underlines the importance of testing a recent sample in genomics‐based precision medicine for metastatic prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci

Author

Fontugne, Jacqueline, primary, Cai, Peter Y., additional, Alnajar, Hussein, additional, Bhinder, Bhavneet, additional, Park, Kyung, additional, Ye, Huihui, additional, Beg, Shaham, additional, Sailer, Verena, additional, Siddiqui, Javed, additional, Blattner-Johnson, Mirjam, additional, Croyle, Jaclyn A., additional, Noorzad, Zohal, additional, Calagua, Carla, additional, MacDonald, Theresa Y., additional, Axcrona, Ulrika, additional, Bogaard, Mari, additional, Axcrona, Karol, additional, Scherr, Douglas S., additional, Sanda, Martin G., additional, Johannessen, Bjarne, additional, Chinnaiyan, Arul M., additional, Elemento, Olivier, additional, Skotheim, Rolf I., additional, Rubin, Mark A., additional, Barbieri, Christopher E., additional, and Mosquera, Juan Miguel, additional

Published
2022
Full Text
View/download PDF

22. Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomy

Author

Tryggestad, Anne M. A., primary, Axcrona, Karol, additional, Axcrona, Ulrika, additional, Bigalke, Iris, additional, Brennhovd, Bjørn, additional, Inderberg, Else M., additional, Hønnåshagen, Turid K., additional, Skoge, Lisbeth J., additional, Solum, Guri, additional, Sæbøe‐Larssen, Stein, additional, Josefsen, Dag, additional, Olaussen, Richard W., additional, Aamdal, Steinar, additional, Skotheim, Rolf I., additional, Myklebust, Tor Å., additional, Schendel, Dolores J., additional, Lilleby, Wolfgang, additional, Dueland, Svein, additional, and Kvalheim, Gunnar, additional

Published
2021
Full Text
View/download PDF

25. Long‐term first‐in‐man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high‐risk prostate cancer after radical prostatectomy.

Author

Tryggestad, Anne M. A., Axcrona, Karol, Axcrona, Ulrika, Bigalke, Iris, Brennhovd, Bjørn, Inderberg, Else M., Hønnåshagen, Turid K., Skoge, Lisbeth J., Solum, Guri, Sæbøe‐Larssen, Stein, Josefsen, Dag, Olaussen, Richard W., Aamdal, Steinar, Skotheim, Rolf I., Myklebust, Tor Å., Schendel, Dolores J., Lilleby, Wolfgang, Dueland, Svein, and Kvalheim, Gunnar

Published
2022
Full Text
View/download PDF

29. Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity

Author

Løvf, Marthe, primary, Zhao, Sen, additional, Axcrona, Ulrika, additional, Johannessen, Bjarne, additional, Bakken, Anne Cathrine, additional, Carm, Kristina Totland, additional, Hoff, Andreas M., additional, Myklebost, Ola, additional, Meza-Zepeda, Leonardo A., additional, Lie, A. Kathrine, additional, Axcrona, Karol, additional, Lothe, Ragnhild A., additional, and Skotheim, Rolf I., additional

Published
2019
Full Text
View/download PDF

30. Abstract CT016: A first in man phase I/II adjuvant dendritic cell vaccine study in high-risk prostate cancer patients following radical surgery reduce the incidence of biochemical relapse

Author

Tryggestad, Anne Merete, primary, Bigalke, Iris, additional, Axcrona, Karol, additional, Brennhovd, Bjørn, additional, Hønnåshagen, T Kirsti, additional, Skoge, Lisbeth, additional, Tjeldhorn, Lena, additional, Mowinckel, Lene, additional, Sæbøe-Larsen, Stein, additional, Jørgensen, Jens A L, additional, Andreassen, Grete S, additional, Skorstad, Gjertrud, additional, Josefsen, Dag, additional, Axcrona, Ulrika, additional, Aamadal, Steinar, additional, Lilleby, Wolfgang, additional, Dueland, Svein, additional, and Kvalheim, Gunnar, additional

Published
2018
Full Text
View/download PDF

32. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study

Author

Beisland,Christian, Johannesen,Tom, Klepp,Olbjorn, Axcrona,Ulrika, Torgersen,Knut Martin, Kowalski,Jan, Solli,Oddvar, Sandin,Rickard, Oldenburg,Jan, Beisland,Christian, Johannesen,Tom, Klepp,Olbjorn, Axcrona,Ulrika, Torgersen,Knut Martin, Kowalski,Jan, Solli,Oddvar, Sandin,Rickard, and Oldenburg,Jan

Abstract

Christian Beisland,1,2 Tom B Johannesen,3 Olbjorn Klepp,4 Ulrika Axcrona,5 Knut Martin Torgersen,6 Jan Kowalski,7 Oddvar Solli,6 Rickard Sandin,8 Jan Oldenburg9,10 1Department of Urology, Haukeland University Hospital, 2Department of Clinical Medicine, University of Bergen, Bergen, 3Department of Registration, Cancer Registry of Norway, Oslo, 4Department of Oncology, Ålesund Hospital, Ålesund, 5Department of Pathology, Oslo University Hospital, the Norwegian Radium Hospital, Oslo, 6Pfizer AS, Oslo, Norway; 7JK Biostatistics AB, Stockholm, 8Pfizer AB, Sollentuna, Sweden; 9Department of Oncology, Akershus University Hospital, Lørenskog, 10Medical Faculty, University of Oslo, Oslo, Norway Background: This population-wide retrospective, non-interventional registry study assessed changes in overall survival (OS) and factors influencing OS in Norwegian patients with renal cell carcinoma (RCC). Methods: Two population-wide health registries were used to identify all RCC patients with (mRCC) or without metastases diagnosed before (2002–2005) and after (2006–2008 and 2009–2011) introduction of targeted therapies. Median OS was estimated using Kaplan–Meier method. Cox proportional hazards regression modeling was used to identify prognostic factors. Results: Overall, 5,463 patients were diagnosed with RCC during 2002–2005 (n=1,898), 2006–2008 (n=1,631), and 2009–2011 (n=1,934); of these, 1,678 (31%) had mRCC. Patients diagnosed in 2009–2011 and 2006–2008 had significant (P<0.001) improvements in OS versus those diagnosed in 2002–2005: median OS, not reached and not reached versus 82.0 months in RCC; 14.0 and 12.0 months versus 9.0 months in mRCC. Similarly, OS improvements were seen in the primary and elderly (≥75 years) mRCC populations. Median OS was comparable (12 months) between clear c

Published
2017

34. Abstract 1745: Multifocal prostate cancer has high degree of genomic heterogeneity

Author

Løvf, Marthe, primary, Zhao, Sen, additional, Axcrona, Ulrika, additional, Johannesen, Bjarne, additional, Hoff, Andreas M., additional, Bakken, Anne Cathrine, additional, Carm, Kristina Totland, additional, Myklebost, Ola, additional, Meza-Zepeda, Leonardo A., additional, Lie, Agnes K., additional, Axcrona, Karol, additional, Lothe, Ragnhild A., additional, and Skotheim, Rolf I., additional

Published
2017
Full Text
View/download PDF

37. Abstract 2235: Clinical results of a Phase I/II trial of adjuvant therapeutic vaccination in high risk resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and survivin

Author

Tryggestad, Anne Merete Aa., primary, Axcrona, Karol, additional, Bigalke, Iris, additional, Inderberg-Suso, Else M., additional, Skorstad, Gjertrud, additional, Axcrona, Ulrika, additional, Aamdal, Steinar, additional, Gaudernack, Gustav, additional, Schendel, Dolores, additional, Lilleby, Wolfgang, additional, Dueland, Svein, additional, and Kvalheim, Gunnar, additional

Published
2016
Full Text
View/download PDF

39. Dendritic and lymphocytic cell infiltration in prostate carcinoma

Author

Yishan, Liu, Thorstein, Sæter, Vlatkovic, Ljiljana, Servoll, Einar, Waaler, Gudmund, Axcrona, Ulrika, Giercksky, Karl- Erik, Nesland, Jahn M., Zhen-He, Suo, and Axcrona, Karol

Subjects
Prostate cancer, 5 - Ciencias puras y naturales::57 - Biología::576 - Biología celular y subcelular. Citología [CDU], CD1a
Abstract

We examined the distribution of CD1a+ cells and CD8+ and CD4+ T lymphocytes in prostate cancer (PCa) and correlated these with clinicopathological parameters. We also investigated whether the distribution of these cells was related to the expression of the cell membrane protein B7-H3, a putative negative regulator of the immune response expressed on PCa cells. A cohort of 151 PCa patients treated with radical prostatectomy (RP) was followed prospectively from 1985 until 2006 with a median follow-up of 9 years. Whole-mount sections of PCa specimens were immunostained to identify immune cells. A low number of CD1a+ cells was significantly associated with a high Gleason score and high pathological stage of pT3. The number of CD1a+ cells correlated significantly with the number of intratumoral and stromal CD8+ and stromal CD4+ lymphocytes. Kaplan-Meier analysis showed a tendency toward impaired biochemical progression-free survival in patients with few CD1a+ cells within their RP specimens. The expression of B7-H3 correlated inversely with the number of CD1a+ cells and intratumoral CD4+ lymphocytes; there was a trend for a similar inverse relationship between B7-H3 expression and the number of CD8+ lymphocytes. Our findings suggest that high-grade prostate carcinoma cells manipulate the immune system and that these changes contribute to the mechanism underlying tumor escape from immune surveillance.

Published
2013

44. SHBG Is an Important Factor in Stemness Induction of Cells by DHT In Vitro and Associated with Poor Clinical Features of Prostate Carcinomas

Author

Ma, Yuanyuan, primary, Liang, Dongming, additional, Liu, Jian, additional, Wen, Jian-Guo, additional, Servoll, Einar, additional, Waaler, Gudmund, additional, Sæter, Thorstein, additional, Axcrona, Karol, additional, Vlatkovic, Ljiljana, additional, Axcrona, Ulrika, additional, Paus, Elisabeth, additional, Yang, Yue, additional, Zhang, Zhiqian, additional, Kvalheim, Gunnar, additional, Nesland, Jahn M., additional, and Suo, Zhenhe, additional

Published
2013
Full Text
View/download PDF

49. Islet Perturbations in Rats Fed a High-Fat Diet

Author

Ahrén, Bo, primary, Gudbjartsson, Tomas, additional, Al-Amin, Ali Naser, additional, Mårhensson, Hans, additional, Myrsén-Axcrona, Ulrika, additional, Karlsson, Sven, additional, Mulder, Hindrik, additional, and Sundler, Frank, additional

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results